Public Workshop: Diabetes Outcome Measures Beyond Hemoglobin A1c

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Public Workshop: Diabetes Outcome Measures Beyond Hemoglobin A1c

	August 2016 www.fda.gov/womens Public Workshop: Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c) On August 29, 2016, FDA’s Center for Drug Evaluation and Research (CDER), is sponsoring a public workshop entitled “Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c).” The purpose of this public workshop is to have a forum for dialogue on the extent to which the current regulatory paradigm for antidiabetic drug therapies addresses the needs of patients with diabetes and to identify additional outcomes, beyond HbA1c. View the Meeting Announcement Please share this update with your network, members, constituents, and community. FDA Office of Women’s Health 10903 New Hampshire Avenue WO32 - Room 2333 Silver Spring, MD 20993-0002 301-796-9440

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)